
OMED
Other · Other
Latest report
Time not confirmed
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Mar 31, 2019
EPS trend, 90 days to now · +100.0% over 90 days · 30-day revisions 0 up, 0 down
Beat estimates in 4 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Dec 31, 2018 | Time not confirmed | -0.22 | -0.12 | +45.5% |
| Nov 1, 2018 | Time not confirmed | -0.20 | 0.16 | +180.0% |
| Aug 2, 2018 | Time not confirmed | -0.23 | -0.10 | +56.5% |
| May 8, 2018 | Time not confirmed | -0.22 | -0.15 | +31.8% |
| Feb 8, 2018 | Time not confirmed | -0.33 | 0.25 | +175.8% |
OncoMed Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel therapeutics that address the fundamental biology driving cancer's growth, resistance, recurrence, and metastasis. It is developing Navicixizumab (anti-DLL4/VEGF Bispecific, OMP-305B83), a monoclonal antibody that targets Delta-like ligand 4 and vascular endothelial growth factor, which has…